Results of the FDA pivotal clinical trial for the LightTouch Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI). In the new LightTouch study, 32% of cervical precancers and cancers were missed by the current method of human papillomavirus (HPV) testing and colposcopy.